Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mesalazine- (5-aminosalicylic acid-) containing products are a well-known treatment for inflammatory bowel disease, often as first line. Myocarditis is recognized as a very rare possible side effect of this drug treatment. We present a case of mesalazine-induced myopericarditis that was successfully improved by immediate cessation of the medication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523686 | PMC |
| http://dx.doi.org/10.1155/2015/728310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesalazine-induced myocarditis in a patient with ulcerative colitis: a case report.
Eur Heart J Case Rep
September 2024
Department of Cardiology, St George's Hospital, Blackshaw Road, London SW17 0QT, United Kingdom.
Background: Mesalazine is an established first-line therapy for inflammatory bowel disease (IBD) and remains the mainstay of treatment for mild to moderate ulcerative colitis (UC). Both mesalazine and UC are rare but recognized causes of myopericarditis. Cardiac magnetic resonance (CMR) is a non-invasive method of assessing for myopericarditis.
View Article and Find Full Text PDFMesalazine-induced myopericarditis: a case series.
Eur Heart J Case Rep
September 2023
Division of Structural Interventional Cardiology, University Hospital Careggi, Largo Brambilla 3, 50133 Florence, Italy.
Background: Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the gastrointestinal tract but can have multiorgan involvement. Mesalazine (5-ASA) is a key therapeutic agent in IBD. Mesalazine has rare but potentially life-threatening side effects such as cardiac injury.
View Article and Find Full Text PDFSuccessful Treatment with Corticosteroids in an 11-Year-Old Patient with Crohn's Disease and Myopericarditis-Case Report.
Pediatr Rep
January 2022
Department of Pediatrics, Gastroenterology, Hepatology, Nutrition and Allergology, Medical University of Bialystok, Waszyngtona St. 17, 15-274 Białystok, Poland.
Extraintestinal manifestations (EIMs) are observed in 15-20% of patients with inflammatory bowel disease (IBD). One of the rare EIMs is myocarditis, the incidence of which is estimated at around 1%. The main cause of myocarditis is a viral infection.
View Article and Find Full Text PDFMesalazine-induced myopericarditis: a case report.
Eur Heart J Case Rep
February 2021
Cardiology Department, South Warwickshire NHS Foundation Trust, Lakin Road, Warwick CV34 5BW, UK.
Background: Mesalazine is a well-established 1st line treatment for inflammatory bowel disease (IBD). Cardiotoxicity following 5-aminosalicyclic-acid therapy remains a rare yet serious complication and can often be challenging to distinguish from myocarditis presenting as an extra-intestinal manifestation of IBD.
Case Summary: We present a case of a 22-year-old man with a background of ulcerative colitis commenced on a mesalazine preparation for disease progression.
Plasma N-terminal pro-B-type natriuretic peptide (BNP) in mesalazine-induced myopericarditis.
BMJ Case Rep
April 2019
Cardiology and Medicine, Frimley Health NHS Foundation Trust, Slough, Berkshire, UK.
Mesalazine (5-aminosalicylic acid)-based products are a widely used treatment for inflammatory bowel disease in children and adults. Associated myopericarditis is an uncommon but recorded phenomenon related to drug hypersensitivity. Unless recognised, this important complication may culminate in the development of dilated cardiomyopathy and severe heart failure.
View Article and Find Full Text PDF